Used in the manufacture of control solutions for Rubella testing and ToRCH screening for perinatal diseases, the synthetic Rubella IgM disease-state serum from BBI Solutions, Cardiff, United Kingdom, is formulated in delipidated, defibrinated plasma that has been designed to mimic a high-titre native Rubella IgM disease-state serum. The product has been tested across multiple test platforms, including Abbott Architect, Siemens Immulite 1000, Roche Cobas, and bioMérieux Vidas. The synthetic serum offers high reproducibility and consistent concentration and recovery across batches, which would not be possible with native material. It is also negative for Rubella IgG, eliminating the risk of false positives. These features make it suitable for use as a raw material when developing controls and calibrators to support assay development and test manufacturing. For more information, contact BBI Solutions.